The University of Chicago Header Logo

Connection

George Perry to Alzheimer Disease

Back to Details
This is a "connection" page, showing publications George Perry has written about Alzheimer Disease.
George Perry
Connection Strength
5.973
Alzheimer Disease
  1. The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Lab Invest. 2019 07; 99(7):958-970.
    View in: PubMed
    Score: 0.513
  2. The complexities of the pathology-pathogenesis relationship in Alzheimer disease. Biochem Pharmacol. 2014 Apr 15; 88(4):671-6.
    View in: PubMed
    Score: 0.361
  3. Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease. Antioxid Redox Signal. 2013 Jun 20; 18(18):2444-57.
    View in: PubMed
    Score: 0.334
  4. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res. 2012 Nov; 43(8):694-8.
    View in: PubMed
    Score: 0.331
  5. Mark A. Smith: neurocytochemistry innovator. J Neurochem. 2012 Mar; 120(6):1139-40.
    View in: PubMed
    Score: 0.314
  6. Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radic Biol Med. 2012 Feb 01; 52(3):699-704.
    View in: PubMed
    Score: 0.310
  7. Mark A. Smith: the scientist, the man. Int J Exp Pathol. 2011 Oct; 92(5):297-8.
    View in: PubMed
    Score: 0.308
  8. Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother. 2010 Jul; 10(7):1201-8.
    View in: PubMed
    Score: 0.282
  9. Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches. Int J Mol Sci. 2009 Mar; 10(3):1386-1406.
    View in: PubMed
    Score: 0.258
  10. RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathol. 2009 Jul; 118(1):151-66.
    View in: PubMed
    Score: 0.258
  11. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol. 2003 Dec; 106(6):552-6.
    View in: PubMed
    Score: 0.176
  12. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol. 2003 May; 162(5):1623-7.
    View in: PubMed
    Score: 0.172
  13. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals. 2003 Mar; 16(1):77-81.
    View in: PubMed
    Score: 0.170
  14. No Evidence of Increased Chronic Traumatic Encephalopathy Pathology or Neurodegenerative Proteinopathy in Former Military Service Members: A Preliminary Study. J Alzheimers Dis. 2019; 67(4):1277-1289.
    View in: PubMed
    Score: 0.127
  15. Cerebrovascular and mitochondrial abnormalities in Alzheimer's disease: a brief overview. J Neural Transm (Vienna). 2016 Feb; 123(2):107-11.
    View in: PubMed
    Score: 0.097
  16. Apolipoprotein E4 prevents growth of malaria at the intraerythrocyte stage: implications for differences in racial susceptibility to Alzheimer's disease. J Health Care Poor Underserved. 2013 Nov; 24(4 Suppl):70-8.
    View in: PubMed
    Score: 0.089
  17. Antimicrobial peptide ß-defensin-1 expression is upregulated in Alzheimer's brain. J Neuroinflammation. 2013 Oct 18; 10:127.
    View in: PubMed
    Score: 0.089
  18. Is exercise-in-a-bottle likely to proffer new insights into Alzheimer's disease? J Neurochem. 2013 Oct; 127(1):4-6.
    View in: PubMed
    Score: 0.088
  19. The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors. 2012 Mar-Apr; 38(2):133-8.
    View in: PubMed
    Score: 0.080
  20. Mark A. Smith, 1965-2010: consummate student of pathogenesis. Int J Clin Exp Pathol. 2011; 4(7):731-2.
    View in: PubMed
    Score: 0.077
  21. A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules. Lab Invest. 2011 Dec; 91(12):1777-86.
    View in: PubMed
    Score: 0.077
  22. Widespread distribution of reticulon-3 in various neurodegenerative diseases. Neuropathology. 2010 Dec; 30(6):574-9.
    View in: PubMed
    Score: 0.073
  23. Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother. 2010 May; 10(5):683-91.
    View in: PubMed
    Score: 0.070
  24. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep. 2010; 15(4):161-8.
    View in: PubMed
    Score: 0.068
  25. Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging (Albany NY). 2009 Apr; 1(4):382-8.
    View in: PubMed
    Score: 0.065
  26. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis. 2009; 18(2):447-52.
    View in: PubMed
    Score: 0.064
  27. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int. 2009 Feb; 54(2):84-8.
    View in: PubMed
    Score: 0.063
  28. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol. 2008 Jun; 67(6):523-31.
    View in: PubMed
    Score: 0.061
  29. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem. 2008 Aug; 106(3):1350-6.
    View in: PubMed
    Score: 0.061
  30. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother. 2008 Apr-May; 62(4):199-207.
    View in: PubMed
    Score: 0.060
  31. The role of novel chitin-like polysaccharides in Alzheimer disease. Neurotox Res. 2007 Dec; 12(4):269-74.
    View in: PubMed
    Score: 0.059
  32. Iron: the Redox-active center of oxidative stress in Alzheimer disease. Neurochem Res. 2007 Oct; 32(10):1640-5.
    View in: PubMed
    Score: 0.057
  33. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother. 2007 May; 7(5):473-85.
    View in: PubMed
    Score: 0.057
  34. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther. 2007 Jun; 321(3):823-9.
    View in: PubMed
    Score: 0.056
  35. Increased expression of p130 in Alzheimer disease. Neurochem Res. 2007 Apr-May; 32(4-5):639-44.
    View in: PubMed
    Score: 0.054
  36. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol. 2006 Jul; 65(7):631-41.
    View in: PubMed
    Score: 0.053
  37. Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. Sci Aging Knowledge Environ. 2006 May 03; 2006(8):pe10.
    View in: PubMed
    Score: 0.053
  38. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol. 2006 Jun; 111(6):503-9.
    View in: PubMed
    Score: 0.053
  39. Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen. 2006 Mar-Apr; 21(2):126-30.
    View in: PubMed
    Score: 0.052
  40. Chitin-like polysaccharides in Alzheimer's disease brains. Curr Alzheimer Res. 2005 Oct; 2(4):419-23.
    View in: PubMed
    Score: 0.051
  41. Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective? Int J Exp Pathol. 2005 Jun; 86(3):133-8.
    View in: PubMed
    Score: 0.050
  42. Oxidative stress and neurodegeneration. Ann N Y Acad Sci. 2005 Jun; 1043:545-52.
    View in: PubMed
    Score: 0.050
  43. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev. 2004 Jul; 3(3):319-26.
    View in: PubMed
    Score: 0.047
  44. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol Aging. 2004 May-Jun; 25(5):599-602; discussion 603-4.
    View in: PubMed
    Score: 0.046
  45. Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. J Neurosci Res. 2004 Mar 01; 75(5):698-703.
    View in: PubMed
    Score: 0.045
  46. Prion disease and Alzheimer's disease: pathogenic overlap. Acta Neurobiol Exp (Wars). 2004; 64(1):11-7.
    View in: PubMed
    Score: 0.045
  47. The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol. 2011 Jul; 70(7):578-87.
    View in: PubMed
    Score: 0.019
  48. Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease. J Neurosci Methods. 2010 Jul 15; 190(2):244-7.
    View in: PubMed
    Score: 0.017
  49. Phosphorylated tau: toxic, protective, or none of the above. J Alzheimers Dis. 2008 Aug; 14(4):377-83.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.